Aimovig Priced ‘Well Below’ Part D Specialty Threshold To Avoid Coinsurance
Amgen-Novartis pricing strategy seeks to ensure patients are subject to flat copays rather than coinsurance, which is calculated as a percentage of drug's list price.
You may also be interested in...
Look for Administration to take credit for any positive pricing news as President says several firms will 'announce voluntary massive drops in prices.'
Amgen and Novartis won the first US FDA approval for a CGRP inhibitor in the prevention of migraine headaches. The companies aim to quickly capture a big share of what they estimate to be an 8m-patient market in the US with a $6,900 per year price tag.
Draft cost effectiveness report released by the Institute for Clinical and Economic Review uses $8,500 annual cost for Aimovig and fremanezumab as a "placeholder" price.